Insider Buying: Immunocore Holdings plc (NASDAQ:IMCR) Director Acquires 807,338 Shares of Stock

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) Director Bros. Advisors Lp Baker purchased 807,338 shares of the business's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the transaction, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. This trade represents a 60.40 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Immunocore Price Performance

Shares of IMCR stock traded down $0.62 on Friday, reaching $29.81. 440,012 shares of the company were exchanged, compared to its average volume of 436,318. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -31.38 and a beta of 0.79. Immunocore Holdings plc has a 1 year low of $27.19 and a 1 year high of $66.00. The business has a 50-day moving average price of $29.99 and a 200 day moving average price of $31.12. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IMCR shares. HC Wainwright reissued a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 target price on shares of Immunocore in a report on Wednesday, March 12th. Finally, Morgan Stanley reissued an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $65.64.

Remove Ads

Institutional Investors Weigh In On Immunocore

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Immunocore by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock worth $1,047,000 after acquiring an additional 420 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Immunocore during the fourth quarter worth $25,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after buying an additional 960 shares in the last quarter. NEOS Investment Management LLC raised its holdings in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after acquiring an additional 1,102 shares during the last quarter. Finally, Pier Capital LLC lifted its stake in Immunocore by 1.4% in the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company's stock worth $2,568,000 after purchasing an additional 1,174 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.